JPRN-UMIN000007020
Completed
Phase 2
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis - Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis
ung Oncology Group in Kyushu, Japan (LOGIK)0 sites32 target enrollmentJanuary 5, 2012
Conditionson-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer
- Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Enrollment
- 32
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Prior elrotinib treatment with the exception of elrotinib discontinuation for four weeks or more at study enrollment. 2\)Active interstitial pneumonia or pulmonary fibrosis on chest CT scan 3\)Severe drug allergy 4\)Prior radiotherapy to chest within 2 weeks 5\)Massive pleural effusion, ascites or pericardial effusion 6\)Active infection 7\)Continuous watery diarrhea 8\)Intestinal paralysis or ileus 9\)Symptomatic ophthalmologic disease 10\)Current or previous (within the last 1 year) gastrointestinal perforation 11\)Severe ulcer 12\)Severe cardiac disease 13\)Severe psychological disease 14\)Pregnant or breast\-feeding females or those who declined contraception 15\)Inappropriate patients for this study judged by the attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43
Completed
Not Applicable
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
Completed
Phase 2
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54